Customised Services in Preclinical Inflammation

News

Latest news updates

Redoxis and Amarna Therapeutics receive EUREKA Eurostars grant for project ALPHAVAC

We are happy to announce that Redoxis, together with our Dutch partner Amarna Therapeutics has been awarded a €0,8 million grant from EUREKA Eurostars to establish a screening platform for the advancement of potential first-in-class gene therapy for ALS and other neurodegenerative diseases using Amarna´s proprietary SVec viral vector platform.

Read more

Redoxis in collaborative project to study inflammation in vascular disease

We are happy to announce that Redoxis AB is a partner in a research project called “Targeting he melanocortin system as a novel strategy to reduce inflammation during vascular disease” led by Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The project was funded by a research grant of SEK 4 million from The Knowledge Foundation, funding research and competence development at Swedish universities. Redoxis will contribute to the project, that is planned to start 1st of July 2021, with expertise in preclinical drug development and efficacy assessment in both disease models and functional assays. “Participating in this project is in line with Redoxis aim to continuously expand competence area, implement new clinically relevant models and stay closely connected with academic research in our quest to be the best contract research organization in preclinical inflammatory research” says Malin Hultqvist Hopkins, CEO of Redoxis AB The project is a collaboration between Örebro University, SynAct Pharma AB and Redoxis AB.

Read more

Redoxis is once again accredited for CIR (French Research Tax Reduction)

Redoxis has been granted approval for the French research tax credit (CIR) for 2021, 2022 and 2023 from the French Ministry of Higher Education and R...

Read more

We are increasing our In Vitro service capacity

This week we are welcoming Linda Reimer Rasmusson back to Redoxis. Linda started her carreer at Redoxis and is now returning to strengthen our In Vit...

Read more

Welcome Tekla!

The newest addition to our team is Tekla Franzén. Tekla is a trained animal technician and held her the most recent position at the Lund University a...

Read more

Are you our new collegue?

We have an open position for a laboratory technician with focus on in vivo work (försöksdjurstekniker). Read more here or contact us directly for mor...

Read more

Models of cytokine release for evaluation of efficacy in acute innate inflammatory responses

Recently, much attention has been given the role of proinflammatory cytokines in pathology of COVID-19. Massive release of cytokines, cytokine storm,...

Read more

Redoxis announces approved Eurostars funding for project E!114520 - ACTION

We are very happy to announce that our joint project application E!114520 ACTION has been approved as a Eurostars labelled project and funding by the...

Read more

We are growing even stronger

A warm welcome to Jens Holmberg, PhD, the latest addition to our team. Jens has a background in preclinical inflammation research with extensive expe...

Read more

Cell based 3D immunology assays: mimicking in vivo structures in models of inflammation

We are continuously adding more assays and models to our portfolio while also actively improving our current models. In collaboration with Cellevate ...

Read more

Redoxis AB signs a 3-year agreement with Taconic Biosciences, Inc.

Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular composition of Taconic’s humanized immun...

Read more

Registered US trademark

As of beginning of March, Redoxis is now a registered trademark in the US. Redoxis has previously been a registered trademark in Sweden and European ...

Read more

We are fully operational

The current Covid-19 situation is clearly affecting all of us but Redoxis CRO services are still fully operational. In addition to our already valida...

Read more

Redoxis´ first PhD student

Alex Moreno joined our company fall of 2018 as an early stage researcher through the European Training Network COSMIC, funded from the European Union...

Read more

Master project available

Successful translation of in vitro results to in vivo proof of concept data is essential in early drug development. Traditionally, in vitro models ha...

Read more

New lab celebration

In the end of December, Redoxis moved into new lab facilities within Medicon Village. With increased lab space and more offices, the new facilities a...

Read more

NeutroCure kick-off meeting

Last week, we successfully kicked off the Horizon 2020 funded FETOPEN program NeutroCure (agreement No 861878). The consortium, with partners from Fr...

Read more

Eurostars Butterfly project meeting

The H2020 funded Eurostars project BUTTERFLY (E! 12979) is well off and in full speed ahead. This week we had a joint meeting with the collaborating ...

Read more

BioFit 2019

Next week, our Senior scientist PhD Francesco Bez will be at the BioFit meeting in Marseille. Francesco is specialising in neurodegenerative diseases...

Read more

Educational day with Redoxis founders

We started off this week with an educational day including presentations from Professor Rikard Holmdahl and Peter Olofsson on Redoxis background and ...

Read more

Standardized preparation of emulsions results in less variation in vivo - a collaboration with BTB Emulsions

As part of our internal efforts to standardize in vivo models to decrease inter-experimental variations, we have evaluated the POWER emulsion prepara...

Read more

Pharma Outsourcing 2019

Come and meet with us during the annual Pharma outsourcing meeting in Stockholm taking place the 10th of December. The meeting includes both presenta...

Read more

Bio-Europe 2019

This week we are excited to attend the 25th edition of Bio-Europe. Redoxis is represented by CEO Malin Hultqvist Hopkins and we are looking forward to...

Read more

Publication on effects of ROS on handling of necrotic cells

Recently, our manuscript "NOX2 mediates quiescent handling of dead cell remnants in phagocytes" was published in Redox Biology. The paper describes th...

Read more

Redoxis receives Horizon 2020 grant

The FET Open Horizon 2020 project under acronym NeutroCure, in which Redoxis is one of the partners, has been granted by the EU commission. The projec...

Read more

BioPharm America

During September, CEO Malin Hultqvist Hopkins attended the BioPharm America partnering meeting in Boston, MA. This was the first meeting attended by R...

Read more

BioEurope spring 2019

We are in full preparation for the BioEurope spring in Wienna taking place 25th to 27th March. We will be happy to catch up on your needs for preclini...

Read more

Open position

We are looking for a new member of our in vivo team. Preferably you have a background with preclinical inflammation models and contract research. For ...

Read more

Meet us att BioEurope

Redoxis will be represented at BioEurope taking place in Copenhagen 5-7th of November. Come meet us at our stand (#110) or book a one-to-one meeting t...

Read more

Redoxis receives CIR (French Research Tax Credit) accreditation

Redoxis has been granted approval for the French research tax credit (CIR) for 2018, 2019 and 2020 from the French Ministry of Higher Education and Re...

Read more

Nordic life science days 2018

Next week Malin Hultqvist Hopkins (CEO) will be at the Nordic Life Science days (NLS days) in Stockholm. Get in touch if you are attending and would l...

Read more

Brain Gain

Redoxis is today at Brain Gain Sweden! Francesco Bez is a speaker during the innovation panel (aging brain disorders) presenting our latest developmen...

Read more

Meet us at the 11th FENS forum of Neuroscience

Francesco Bez will attend the FENS forum of neuroscience taking place in Berlin on the 7-11 of July. We continuously add more models to our portfolio ...

Read more

Redoxis annual summer meeting

Yesterday, Redoxis had its annual summer meeting with many fruitful discussions followed by a tough contest (you might see who was on the winning team...

Read more

Society for free radical research international biannual meeting

As part of the RISE project REDOXIT (Marie Sklodowska-Curie Action) we are present at the SFRRI meeting in Lisbon next week. By attending this meeting...

Read more

Meet us at the Global Discovery to Development Innovation Forum

Francesco Bez will be present at the 11th Global Discovery to Development Innovation Forum (GDDIF) taking place in Amsterdam 16-17th of May. We contin...

Read more

Magnetic resonance imaging in animal models

Established under the Eurostars E9215 (IMAID) program, Redoxis can now offer magnetic resonance imaging services in animal models. Redoxis offer, toge...

Read more

Meet us at BioEurope Spring

Malin H Hopkins (CEO) will be present at BioEurope Spring taking place in Amsterdam 12-14th of March. We continuously add more models to our portfolio...

Read more

NEW - In vivo models of Psoriasis and Psoriatic arthritis

Redoxis is now proud to offer models of Psoriasis (IMQ model) and Psoriatic Arthritis (MiP) model. Psoriasis is a common autoimmune disease affecting ...

Read more

Newest member of our team - Frida

We are, since december, happy to have Frida on our team of researchers. Frida just finished her master in molecular biology at the University of Lund ...

Read more

Applications invited

Applications are invited for 14 ESRs (Early Stage Researchers) funded by the Marie-Sklodowska-Curie Innovative Training Network COSMIC (Combatting dis...

Read more

Redoxis a part of COSMIC

As of the first of January 2018 Redoxis is a part of the international consortium COSMIC. COSMIC systems medicine training and research programme kic...

Read more

Meet us at BioEurope 6-8 November, Berlin

We will be at the BioEurope meeting in Berlin from 6-8 of November. Take the opportunity to meet with us for a presentation of our services and models...

Read more

Want to join our team?

We are looking to expand our team with a person experienced in laboratory work and preclinical in vivo models of inflammatory diseases. More informati...

Read more

NEW - LPS induced acute inflammation in mice

We are continuously adding new, well characterised models to our portfolio and the latest is the LPS induced acute inflammation model in mice. Mice ar...

Read more

Nordic Life Science days 2017

Redoxis will be represented by Sebastian Hansson at the Nordic Life Science (NLS) days in Malmö/Copenhagen the 12th-14th September. Sebastian will be ...

Read more

Meet Sebastian

Since June this year, we are happy to have Sebastian Hansson, Business Development Manager, joint our team. Sebastian will strengthen our competence w...

Read more

We are welcoming Francesco Bez to our team

Starting today, we are happy to have Francesco Bez (PhD) joining our team. Francesco holds a PhD in Neuroscience and is an expert in in vivo models of...

Read more

Meet us at the Future of Swedish and Danish life science days

The future of Swedish and Danish life science days will be taking place the 30th of March at Medicon village in Lund. Redoxis will be represented with...

Read more

BioEurope Spring 2017

Redoxis attended the BioEurope spring partnering meeting in Barcelona 20-22 March. During this successful event we enjoyed meetings with new partners ...

Read more

5-year celebration with Medicon Village

Friday the 20th of January, Medicon Village hosted a large event to celebrate their first 5-years. Their success have been enormous and plans for the ...

Read more

Published paper on effects of cytokines using our rat ex vivo model

The electronic version of our manuscript "Cytokine correlation analysis based on drug perturbation" was recently accepted published after acceptance i...

Read more

Meet us at BioEurope in Cologne 7-9 Nov

Redoxis will, as a part of a delegation of innovative life science companies from Skåne, together with Invest in Skåne participate in the partnering m...

Read more

Pristane induced arthritis (PIA) in focus

Innovative Medicines Initiative BTCure, in which Redoxis is a partner, has combined experience from laboratories worldwide to establish standardised p...

Read more

New CEO

Since May 1st Malin Hultqvist Hopkins, former CSO, is appointed CEO of Redoxis. This change is in line with Redoxis continuous ambition to be a focuse...

Read more

BioEurope is finally in Stockholm

Since BioEurope is one of the main events for partnering and drug development collaborations, Redoxis is during 4-6 April in Stockholm attending the B...

Read more

We are expanding our in vitro/ex vivo analysis capacity

At Redoxis, we have a fully equipped lab for work with both primary cells and cell lines. We also hava fully equipped laboratory for post experiment f...

Read more

Pharmaoutsourcing in Stockholm 9th December

In the 9th of December we will attend the PHARMA OUTSOURCING meeting in Stockholm-  This is a new annual international partnering meeting for Investme...

Read more

NEURINOX gathers top researchers, patients and industry in an international symposium on innovative concepts for treating neurodegenerative diseases

Neurodegeneration leads to chronic debilitating diseases, including age-related syndromes like Alzheimer's and Parkinson's diseases and disorders affe...

Read more

Meeting partners and NLS days in Stockholm 9-10 september

Attending one of the largest partnering event in Life Science, these days taking place in Stockholm 9-10 September- 2015. This will be an event not on...

Read more

Tax reduction eligibility for Redoxis services

Redoxis has been approved by the French authorities "Ministère chargé de l'Enseignement supérieur et de la Recherche" eligible for tax reduction for s...

Read more

RISE - European collaboration with Aston University and University of Erlangen

This month we started the RISE project REDOXIT for Research and Innovation Staff Exchange (RISE) as a collaborative project with Aston University (Bir...

Read more

NEURINOX SYMPOSIUM: INNOVATIVE CONCEPTS FOR TREATING NEURODEGENERATIVE DISEASE

What is the reason behind neuroinflammation involved in the development of neurodegenerative diseases like Amyotrophic lateral sclerosis, Multiple scl...

Read more
Contact